Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment

Key facts

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Principal Investigator

Junichi Hashimoto, PhD

Otsuka Pharmaceutical Co., Ltd Japan (OPCJ)

Intervention

Brexpiprazole(drug)

Enrollment

48 target

Eligibility

18-35 years · All sexes

Timeline

2013 – 2014

Study locations (24)

• Cerritos, California, United States
• Costa Mesa, California, United States
• Garden Grove, California, United States
• Glendale, California, United States
• Orange, California, United States
• Riverside, California, United States
• San Diego, California, United States
• Norwich, Connecticut, United States
• Fort Myers, Florida, United States
• Hialeah, Florida, United States
• Melbourne, Florida, United States
• Orlando, Florida, United States
• Atlanta, Georgia, United States
• Prairie Village, Kansas, United States
• Weymouth, Massachusetts, United States
• +9 more locations on ClinicalTrials.gov

Collaborators

Otsuka Pharmaceutical Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Mal de débarquement

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07422844
  Dynamic Network Response to TMS Treatment
  Goethe University
• RECRUITINGPHASE2NCT06132178
  Psilocybin rTMS for Treatment Resistant Depression
  University of Texas at Austin
• ENROLLING BY INVITATIONNCT06512324
  Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry
  Biomedical Discoveries and Neuroscientific Foundations LLC
• RECRUITINGNANCT05460520
  DevRobust Treatment for Mal de Débarquement Syndrome
  Icahn School of Medicine at Mount Sinai

See all trials for Mal de débarquement →